Objective. The objective of this study was to examine cause-specific mortality in patients with PsA compared with the general population and compared with patients with RA.
Introduction
PsA is a chronic inflammatory arthritis associated with psoriasis. PsA can have a substantial impact on patients' quality of life and functional ability. In addition to joint disease, PsA is also associated with a number of metabolic co-morbidities, including cardiovascular disease, diabetes and obesity as well as psychological co-morbidities, including depression and anxiety [1] . Early clinic-based studies suggested an increased risk of mortality, although this risk improved over time [2] . However, recent studies suggest no increased risk of mortality among patients with PsA [3, 4] . On the contrary, studies in RA have found an increased risk for all-cause mortality and cause-specific mortality, including cardiovascular, respiratory, infection and cancer deaths [5] . Additionally, a populationbased study in psoriasis (although not specifically PsA) found that patients with severe psoriasis have increased cardiovascular, respiratory, infectious and cancer deaths as well [6] .
Although there is not a clear link to increased mortality in PsA, there may be elevated risk of cause-specific mortality, in particular cardiovascular mortality, among patients with PsA compared with the general population.
There is a paucity of data on cause-specific mortality in PsA [7] . Furthermore, no studies have examined causespecific mortality in the general population compared with internal controls as opposed to using clinic-or hospitalbased cohorts and comparing with population statistics. Identification of increased cause-specific mortality in PsA could aid in targeting interventions to reduce death from specific causes. The objective of this study was to examine cause-specific mortality in patients with PsA compared with the general population and compared with patients with RA.
Methods

Study design and data source
A longitudinal cohort study was performed within The Health Improvement Network (THIN) in the UK. Participating general practitioners from 514 general practices record data as a part of routine patient care in the electronic medical record; the data are then collected by THIN and anonymized for use in research. Data from 1994 to September 2010 were included.
Study population
All patients with PsA or RA between the ages of 18 and 89 years at the start date were included. PsA was defined by a single diagnosis code (positive predictive value 85%) [8] . Diagnosis codes for RA have also been previously validated [9] . Patients were excluded if they died or transferred out of the practice before the implementation of software in that practice. We did not restrict the population to 'incident' diagnoses. For each patient with PsA, up to 10 unexposed controls from the general population were randomly selected and were matched on practice and start date within the practice. More detail on patient selection, cohort time and covariate definitions are available in previous publications using this same cohort [3, 10] .
Person-time calculation
Cohort entry was defined as the latest of diagnosis, 6 months after initial registration with the practice, implementation of software in the practice or a practice acceptable mortality reporting. Censoring occurred when the patient died, left the practice, the practice stopped participating in THIN or the study ended in September 2010.
Outcome definition
The primary outcome was cause of death. Death was defined by specific codes noting death and/or codes indicating that the patient was transferred out of the practice because of death [3, 11] . Cause of death was assigned based on an algorithm recommended by Cegedim, the administrators of THIN. We first examined all codes and text comments associated with an administrative or medical code for cause of death and all text comments indicating that a medical code represented the cause of death. For patients without an assigned cause of death after this first step, we then examined medical codes assigned to the patient on the day of their death. Next, we examined the medical codes and text comments within the following time periods sequentially: 180 days after the death date (as some codes may be entered later) and then 10, 30 and finally 60 days before the death date. We continued to look through each period until a patient was assigned a cause of death. If there were not medical codes within the 60 days before or 180 days after the death date, the patient was assigned to the unknown category. We then assigned a cause-of-death category based on the UK causes of death to facilitate comparison with UK death statistics. Two coders (A.O. and S.M.) assigned cause of death. Any discrepancies were resolved through discussion or involvement of a third coder (Y.J.) when necessary. After the first round of coding, the k statistic for inter-rater agreement between A.O. and S.M. was 0.94.
Statistical analysis
Descriptive statistics were used to examine age, sex, baseline covariates, person-time, covariate distribution and causes of death among the four groups. Competing-risk survival regression models were used to determine the hazard ratio (HR) for each group compared with the unexposed group accounting for the opportunity to die from another cause. Potential confounders, including age, sex, smoking, prior hospitalization in the baseline period, year of cohort entry, socio-economic status (via Townsend deprivation score) and urban vs rural living environment, were tested in the models using a purposeful selection approach, and only covariates that were significant in the model were maintained in the final model. As a sensitivity analysis, we instead used Cox proportional hazards models to determine whether there was a difference based on the models used. All statistical analyses were performed using STATA 13.0 (College Station, TX, USA).
Ethics board approval
All data in this study was anonymous to the investigators. This study was approved by the University of Pennsylvania Institutional Review Board and Cegedim's Scientific Review Committee in the UK.
Results
Among patients with PsA (8706), RA (41 752) and unexposed controls (81 573), 470, 7004 and 5269 deaths were observed, respectively. Baseline characteristics of patients in the study population are presented in Table 1 . Approximately half of patients with PsA and RA had been prescribed a DMARD in the baseline period. Average follow-up time was similar among the groups (5.025.55 years). The average ages at cohort entry and death were older in patients with RA (particularly among patients not on a DMARD), and the average number of causes of death was 1.21 (supplementary Table S1 , available at Rheumatology Online).
The most common cause of death in all groups was cardiovascular disease (supplementary Table S1 , available at Rheumatology Online). Cancer, respiratory and infection were also common causes of death. Approximately onequarter of deaths in the cohort did not have a discernable cause of death. The UK death statistics from 2011 for cause-specific mortality are included in supplementary  Table S1 , available at Rheumatology Online, for reference. The UK statistics do not include unknown cause of death as a category, thus the percentage of deaths is higher for the other groups. However, infectious deaths were more common in our cohort.
Among patients with PsA, there were no significant increases in the age-and sex-adjusted HR for any of the major causes of death compared with unexposed controls (Table 2) Table S2 , available at Rheumatology Online). Finally, we examined some of the more common individual causes of death (supplementary Table S3 , available at Rheumatology Online), although these individual outcomes were relatively rare. Among these more rare causes of death, death from suicide was significantly elevated among patients with both PsA (HR = 3.03, 95% CI: 1.56, 5.90) and RA (HR = 2.47, 95% CI: 1.51, 4.04).
Discussion
In this population-based study, we found that patients with PsA were not at increased risk of specific causes of death, including cardiovascular, respiratory, infection and cancer deaths. This is consistent with our recent papers reporting that patients with PsA do not have a higher risk of mortality or cardiovascular mortality despite an increased risk of cardiovascular events [3, 10] . On the other hand, previous studies examining mortality in specialty clinics have reported an increased risk of mortality, including cardiovascular mortality. The difference in results may be related to the heterogeneity of PsA. Patients with PsA in the general population may have a range of disease activity from very mild to very severe, whereas patients seen in specialty clinics are more likely to have a more severe or active form of the disease. Finally, one important finding was an increase in the HR of deaths attributable to suicide compared with the general population. This is relevant considering recent reports of suicidal ideation in clinical trials for PsA and, to our knowledge, is the first population-based estimate of the risk for suicide in PsA and RA.
In this study, we found substantially increased risk of cardiovascular, respiratory and infectious deaths and a small increased risk of cancer death in RA. The associations between RA and cardiovascular, infection, cancer and respiratory deaths have been previously reported, but the link to respiratory deaths was surprisingly elevated. Similar to England et al. [12] and Sparks et al. [13] , we also found that 15% of deaths were related to respiratory diseases. Likewise, these respiratory deaths were most commonly attributed to chronic obstructive lung disease, asthma and interstitial lung disease (data not shown). Although our HR estimates are attenuated from those reported by these two studies, our findings support the increased risk for respiratory death noted among men enrolled in the Veterans Affairs RA registry and women enrolled in the Nurses Health Study.
To our knowledge, this is the largest study with the greatest number of person-years (an average of > 5 years per person) to date to examine cause of death in PsA and RA. Additional strengths of this study include validated exposure definitions (PsA and RA), the population-based approach and inclusion of an internal unexposed group. Furthermore, causes of death among controls were similar to UK national statistics after accounting for patients unable to be classified [15] . Limitations of the study include lack of death certificate information and the inferential nature of assigning cause of death. In addition, there may be a lack of statistical power, which may be particularly relevant for patients with PsA. Finally, we do not have information on disease activity. It is possible that patients with more severe disease have increased all-cause and cause-specific mortality, and this may have stronger associations with cardiovascular death as well as other specific causes [14] . Note that none of the covariates in the multivariable models changed the point estimates by 5 10%. However, in order to illustrate the relative lack of change accounting for these risk factors for death changed the outcome, we have included the multivariable models. Covariates differed slightly by model but included smoking status, stroke, atrial fibrillation, hypertension, diabetes, hyperlipidaemia, cancer, congestive heart failure, peripheral vascular disease, myocardial infarction, Charlson comorbidity score, Townsend deprivation score, urban vs rural setting and oral glucocorticoid use in the baseline period. HR: hazard ratio.
In conclusion, this large population-based study confirms increased cause-specific mortality in patients with RA but did not find significantly elevated cause-specific mortality in PsA with the exception of suicide which, although a small number of cases overall, was substantially elevated compared with the general population for both RA and PsA. Despite a lack of other cause-specific mortality in PsA, it is equally important to assess and appropriately manage co-morbidities in patients with PsA because they can have significant impact on quality of life and, potentially, longevity [1] .
